Related Experiment Video

Updated: Mar 6, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Hypothesis: ROBOPHERA, a phosphatase and tensin homolog-targeted antineoplastic therapy

Arsalan Azimi1, Arian Azimi

  • 1Shiraz School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Anti-Cancer Drugs
|March 17, 2017
PubMed

Insights

This study explores how ROBOPHERA, a combination of medications, may enhance cancer treatment by boosting PTEN protein activity. The hypothesis suggests this could inhibit cancer growth, metastasis, and improve therapy success rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phosphatase and tensin homolog (PTEN) is a critical tumor suppressor protein.
  • Dysregulation of PTEN is implicated in various cancers.
  • PTEN controls key cellular processes including apoptosis, proliferation, and migration.

Purpose of the Study:

  • To investigate the potential of a novel drug combination (ROBOPHERA) to enhance PTEN expression and activity.
  • To hypothesize the therapeutic benefits of ROBOPHERA in cancer treatment.

Main Methods:

  • The study proposes a combination of Rosiglitazone (RO), Bortezomib (BO), Phosphatidylserine (PH), Ethanol (E), and Radiotherapy (RA) - termed ROBOPHERA.
  • The proposed mechanism involves stimulating PTEN expression and activity.

Main Results:

  • Hypothesized that ROBOPHERA may induce differentiation of cancer stem cells.
  • Anticipated that ROBOPHERA could inhibit cancer progression and metastasis.
  • Predicted that ROBOPHERA may sensitize cancer cells to antineoplastic therapies.

Conclusions:

  • ROBOPHERA presents a potential synergistic approach to cancer therapy.
  • Enhancing PTEN activity via ROBOPHERA could improve treatment efficacy and outcomes.
  • Further research is warranted to validate these therapeutic hypotheses.

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

845
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K